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If treated early, prostate cancer is usually curable. After metastasis occurs, however, these tumors 
become resistant to treatment and are generally fatal. Therefore, inhibiting metastasis may 
significantly improve the survival time for patients with prostate cancer. The Vasioukhin laboratory 
has previously shown that the host serine protease Hepsin promotes prostate cancer progression 
and metastasis using an in vivo mouse model (Klezovitch, et al., 2004). Furthermore, the level of 
Hepsin overexpression in prostate tumors is inversely correlated with clinical outcome. These 
findings suggest that Hepsin may be an excellent target for new chemotherapeutics. Supporting this 
hypothesis in a recent paper published in Oncotarget, Drs. Xi Tang and Valeri Vasioukhin (Human 
Biology Division) and their collaborators demonstrate that a novel small molecule inhibitor of Hepsin, 
HepIn-13, can prevent metastasis in a prostate cancer model system. 
The Vasioukhin laboratory has identified several Hepsin inhibitors for use as lead compounds in 
drug development (Chevillet, et al., 2008). In the current study, Tang and colleagues screened a 
collection of chemical derivatives of a lead compound and identified six small molecules that are 
potent and specific hepsin inhibitors in vitro. The team next tested the pharmacokinetics of these 
candidate compounds in vivo and found that all six compounds had similar half-lives. However, only 
one compound, HepIn-13, was detectable in the blood after oral administration of the compound. 
Therefore, the team focused on determining the activity of HepIn-13 in a prostate cancer model 
system. 
To assess the impact of HepIn-13 on prostate cancer progression in vivo, the authors employed a 
unique mouse-based model of prostate cancer that expresses Hepsin and consistently metastasizes 
to bone. HepIn-13 was administered to mice in their food at one of two different concentrations that 
resulted in blood concentrations above the previously determined IC50. Thirteen weeks after 
treatment was initiated the team did not identify any difference in primary prostate tumors in either 
the control or treated mice (mean tumor size = 2.1 +/- 3.3 g (control) v 1.9 +/- 2.0 g (treated)). 
Excitingly, HepIn-13 significantly reduced the occurrence of metastases over the course of the study. 
While 66% of control mice developed metastases, mice treated with high dose HepIn-13 did not 
develop any metastases and only 30% of low-dose treated developed metastases.  
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This study supports the hypothesis that inhibition of Hepsin may be an effective target to prevent 
metastasis of prostate cancer. Beyond prostate cancer, Hepsin is also overexpressed in a variety of 
other cancer types, raising the possibility that Hepsin inhibition may broadly inhibit the progression of 
several cancers. "One significant limitation of our compound is relatively poor oral bioavailability. 
This will need to be improved on before this compound can be used in people," said Dr. Valeri 
Vasioukhin. 
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Image from Tang, et al., 2014. 
Predicted docking of HepIn-13 (ball and stick model) within the catalytic pocket of Hepsin (grey). 
 
